213 related articles for article (PubMed ID: 20149156)
1. A probable case of transfusion-transmitted hepatitis B virus infection in an immunosuppressed recipient caused by an occult HBV-infected donor with negative ID-NAT.
Leung VK; Lee CK; Chau TN; Cheung WI; Lo FH; Lai KB; Lin CK
Transfus Med; 2010 Aug; 20(4):276-7. PubMed ID: 20149156
[No Abstract] [Full Text] [Related]
2. Is it a case of transfusion-transmitted acute HBV or reactivation of occult hepatitis B virus infection?
Ozaslan E; Purnak T
Transfus Med; 2010 Aug; 20(4):275. PubMed ID: 20534032
[No Abstract] [Full Text] [Related]
3. Occult hepatitis B virus infection.
Allain JP
Transfus Clin Biol; 2004 Feb; 11(1):18-25. PubMed ID: 14980545
[TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
[TBL] [Abstract][Full Text] [Related]
5. Transfusions of red blood cells from an occult hepatitis B virus carrier without apparent signs of transfusion-transmitted hepatitis B infection.
Furuta RA; Kondo Y; Saito T; Tomita M; Oka K; Kishimoto Y; Tani Y; Shibata T
Transfus Med; 2008 Dec; 18(6):379-81. PubMed ID: 19140823
[No Abstract] [Full Text] [Related]
6. Infectivity of HBV DNA positive donations identified in look-back studies in Hyogo-Prefecture, Japan.
Bouike Y; Imoto S; Mabuchi O; Kokubunji A; Kai S; Okada M; Taniguchi R; Momose S; Uchida S; Nishio H
Transfus Med; 2011 Apr; 21(2):107-15. PubMed ID: 21118317
[TBL] [Abstract][Full Text] [Related]
7. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
Busch MP
Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
[TBL] [Abstract][Full Text] [Related]
8. Occult hepatitis B virus infection among anti-HBc positive blood donors: Necessitates substitution of screening by HBV NAT.
Panhotra BR; Bahrani A; Joshi CS; ul Hassan Z
J Infect; 2005 Oct; 51(3):263. PubMed ID: 16125778
[No Abstract] [Full Text] [Related]
9. Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.
Kiely P; Margaritis AR; Seed CR; Yang H;
Transfusion; 2014 Aug; 54(8):2084-91. PubMed ID: 24650170
[TBL] [Abstract][Full Text] [Related]
10. Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations.
Martin LA; Stramer SL; Kuhns MC; Schlauder GG
Transfusion; 2012 Oct; 52(10):2201-8. PubMed ID: 22321072
[TBL] [Abstract][Full Text] [Related]
11. Occult hepatitis B virus infection: implications in transfusion.
Allain JP
Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
[TBL] [Abstract][Full Text] [Related]
12. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
Satake M; Taira R; Yugi H; Hino S; Kanemitsu K; Ikeda H; Tadokoro K
Transfusion; 2007 Jul; 47(7):1197-205. PubMed ID: 17581154
[TBL] [Abstract][Full Text] [Related]
13. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage.
Yoshikawa A; Gotanda Y; Minegishi K; Taira R; Hino S; Tadokoro K; Ohnuma H; Miyakawa K; Tachibana K; Mizoguchi H;
Transfusion; 2007 Jul; 47(7):1162-71. PubMed ID: 17581150
[TBL] [Abstract][Full Text] [Related]
14. Detection of an acute asymptomatic HBsAg negative hepatitis B virus infection in a blood donor by HBV DNA testing.
Weber B; Mühlbacher A; Melchior W
J Clin Virol; 2005 Jan; 32(1):67-70. PubMed ID: 15572009
[TBL] [Abstract][Full Text] [Related]
15. Occult hepatitis B infection and transfusion-transmission risk.
Candotti D; Boizeau L; Laperche S
Transfus Clin Biol; 2017 Sep; 24(3):189-195. PubMed ID: 28673499
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test.
Kleinman SH; Strong DM; Tegtmeier GG; Holland PV; Gorlin JB; Cousins C; Chiacchierini RP; Pietrelli LA
Transfusion; 2005 Aug; 45(8):1247-57. PubMed ID: 16078909
[TBL] [Abstract][Full Text] [Related]
17. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
[TBL] [Abstract][Full Text] [Related]
18. Transient occult hepatitis B virus infection in a blood donor with high viremia.
Bremer CM; Saniewski M; Wend UC; Torres P; Lelie N; Gerlich WH; Glebe D
Transfusion; 2009 Aug; 49(8):1621-9. PubMed ID: 19413737
[TBL] [Abstract][Full Text] [Related]
19. A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases.
Laperche S; Maniez M; Barlet V; El Ghouzzi MH; Le Vacon F; Levayer T; Lunel F; Morel P; Mouillot L; Piquet Y; Pillonel J;
Transfusion; 2008 Nov; 48(11):2308-14. PubMed ID: 18673347
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations.
Bouchardeau F; Girault A; Razer A; Servant-Delmas A; Mercier M; Laperche S
Transfusion; 2006 Dec; 46(12):2047-52. PubMed ID: 17176315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
